文献速递新发突发、热带与寄生虫病

加拿大魁北克省猴痘疫苗单剂有效性的检测阴性设计研究:调整与未调整自报暴露风险

Single-dose Effectiveness of Mpox Vaccine in Quebec, Canada: Test-negative Design With and Without Adjustment for Self-reported Exposure Risk.
PubMed 文献 · Clin Infect Dis · 2024-01-01

在2022年猴痘暴发期间,魁北克省优先为高风险人群接种第一剂疫苗。本研究采用检测阴性病例对照设计,于2022年6月19日至9月24日评估单剂猴痘疫苗有效性(VE)。仅用行政数据调整暴露风险时,单剂VE为35%(95%CI:-2至59);补充自报风险因素后,VE升至65%(95%CI:1至87),提示暴露风险调整不充分可能低估疫苗效果。

要点

  • 仅用行政数据调整暴露风险时,单剂猴痘疫苗有效性为35%(95%CI:-2至59)。
  • 补充自报风险因素后,单剂疫苗有效性升至65%(95%CI:1至87)。
  • 暴露风险调整不充分可能大幅低估猴痘疫苗有效性。

核心结论

  • 仅使用行政数据时,估计单剂疫苗将猴痘风险降低约三分之一;额外调整自报风险因素信息后,单剂疫苗估计将猴痘风险降低约三分之二。
  • 暴露风险调整不充分可能大幅低估猴痘疫苗有效性。

研究设计与样本

  • 研究为检测阴性病例对照研究,于2022年6月19日至9月24日开展。
  • 评估两个研究人群:行政数据库内全部人群(All-Admin,532人)和完成问卷的子集(Sub-Quest,199人,占37%)。
  • 通过问卷收集检测前3周的自报风险因素,补充行政数据库信息。
  • 采用逻辑回归模型调整年龄、日历时间和暴露风险,暴露风险分别仅基于行政指标(All-Admin和Sub-Quest)或补充问卷信息(Sub-Quest)。

主要发现

  • All-Admin人群共532人,其中199人(37%)属于Sub-Quest。
  • 仅基于行政指标调整暴露风险时,单剂VE在All-Admin人群为35%(95%CI:-2至59),在Sub-Quest人群为30%(95%CI:-38至64),两者相似。
  • 补充问卷信息调整后,Sub-Quest人群VE估计值升至65%(95%CI:1至87),置信区间有重叠。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: During the 2022 mpox outbreak, the province of Quebec, Canada, prioritized first doses for pre-exposure vaccination of people at high mpox risk, delaying second doses due to limited supply. We estimated single-dose mpox vaccine effectiveness (VE) adjusting for virus exposure risk based only on surrogate indicators available within administrative databases (eg, clinical record of sexually transmitted infections) or supplemented by self-reported risk factor information (eg, sexual contacts). METHODS: We conducted a test-negative case-control study between 19 June and 24 September 2022. Information from administrative databases was supplemented by questionnaire collection of self-reported risk factors specific to the 3-week period before testing. Two study populations were assessed: all within the administrative databases (All-Admin) and the subset completing the questionnaire (Sub-Quest). Logistic regression models adjusted for age, calendar-time and exposure-risk, the latter based on administrative indicators only (All-Admin and Sub-Quest) or with questionnaire supplementation (Sub-Quest). RESULTS: There were 532 All-Admin participants, of which 199 (37%) belonged to Sub-Quest. With exposure-risk adjustment based only on administrative indicators, single-dose VE estimates were similar among All-Admin and Sub-Quest populations at 35% (95% confidence interval [CI]:-2 to 59) and 30% (95% CI:-38 to 64), respectively. With adjustment supplemented by questionnaire information, the Sub-Quest VE estimate increased to 65% (95% CI:1-87), with overlapping confidence intervals. CONCLUSIONS: Using only administrative data, we estimate one vaccine dose reduced the mpox risk by about one-third; whereas, additionally adjusting for self-reported risk factor information revealed greater vaccine benefit, with one dose instead estimated to reduce the mpox risk by about two-thirds. Inadequate exposure-risk adjustment may substantially under-estimate mpox VE.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Brousseau N, Carazo S, Febriani Y, et al. Single-dose Effectiveness of Mpox Vaccine in Quebec, Canada: Test-negative Design With and Without Adjustment for Self-reported Exposure Risk. Clin Infect Dis. 2024. PMID: 37769158. doi:10.1093/cid/ciad584

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。